Bayer's Dual Narrative: A Diagnostic Breakthrough and a Debt Windfall Reshape the Investment Case

Bayer's cardiology push shows promise as Kerendia sales jump 75%, while debt forecast improves to €29-30B ahead of glyphosate settlement hearing.

The German conglomerate is quietly assembling a growth story that extends well beyond its legal entanglements. On Tuesday, Bayer announced that its Phase-III REVEAL study for the radiotracer Iodine-124-Evuzamitid hit its primary endpoints on sensitivity and specificity, positioning the diagnostic agent as a potential tool for identifying cardiac amyloidosis — a condition frequently diagnosed too late for optimal intervention.

The timing is telling. Just a day earlier, the company unveiled fresh clinical data on two fronts: an expanded indication for its heart and kidney drug Kerendia, and another PET tracer aimed at the same amyloidosis detection market. The clustering of cardiology-focused announcements underscores a deliberate strategy to diversify the pharma division's reliance on established blockbusters.

The Commercial Engine

Kerendia has emerged as the standout performer within the pharma portfolio. First-half sales reached €603 million, a 75 percent jump year-over-year, making it one of the few genuine growth stories in a segment that otherwise largely plateaued during the second quarter. The latest findings, presented Sunday at the ESC cardiology conference in Munich, come from a subgroup analysis of the Phase-III FIND-CKD trial, demonstrating that finerenone slows the decline of kidney function in patients with hypertensive nephropathy — efficacy that stacks on top of existing standard-of-care therapy.

The company is presenting eleven cardiology, renal, and stroke program updates at the conference, which runs through August 31.

A Quarter of Contrasts

The operational picture is one of stabilization, though not without nuance. Second-quarter earnings per share came in at €0.23, a marked improvement from the €0.20 loss recorded in the same period last year. Group revenue rose 1.24 percent to €10.87 billion, while adjusted EBITDA climbed 1.9 percent to €2.14 billion. Core earnings per share, however, declined 16.7 percent to €0.95.

For the first half, Bayer posted revenue of €24.3 billion and EBITDA of €6.6 billion, both growing in the mid-single digits. Management reaffirmed its full-year guidance: revenue between €44.7 billion and €47.0 billion, with core EPS of €4.10 to €4.80.

Leverage Lightens

A quieter but consequential development sits on the balance sheet. Following the capital infusion from Apollo-managed funds for the LARC contraception business — a deal where Bayer retains majority ownership and operational control, expected to close in the third quarter — the company has trimmed its year-end net financial debt forecast from €32–33 billion to €29–30 billion. That revision signals a faster deleveraging path than previously anticipated.

The Legal Calendar

The glyphosate saga remains unresolved, though procedural clarity is emerging. Last Thursday, a U.S. federal appeals court denied a plaintiff group's request to move the proposed Missouri class settlement to California, keeping jurisdiction with the original court. A hearing for final approval of the settlement is now set for September 14, following a joint request by Bayer and plaintiffs' counsel for an extension to process opt-out applications.

Market Positioning

Shares have entered a consolidation phase. Tuesday's trading saw the stock at €48.67, down 0.8 percent from Monday's close of €49.05. The twelve-month picture remains robust: a 74 percent gain, with the stock up roughly 32–33 percent year-to-date depending on the measurement date. At €53.86, the 52-week high reached in early July sits about 9.6 percent above current levels, while the distance from the year's low exceeds 90 percent — a measure of how far the recovery has traveled since the autumn trough.

Investors now face a two-track narrative into the autumn: the September 14 court hearing on the glyphosate settlement, and the continued maturation of a pharma pipeline that increasingly stands on multiple pillars. The next quarterly report, scheduled for November 3, will test whether the operational stabilization has legs — and whether the cardiology offensive can keep delivering commercial momentum.